Peer-Reviewed Research & Proven Results
Low-dose radiotherapy (LDRT) for inflammatory musculoskeletal conditions has been studied extensively in Germany and Europe since the 1980s. The literature spans prospective trials, retrospective analyses, and long-term follow-up studies across multiple joint types and patient populations.
The findings are consistent: response rates between 70 and 90 percent, a well-characterized safety profile, and durable relief lasting 18+ months in the majority of responders. The mechanism is well understood at the cellular level, with documented effects on pro-inflammatory cytokine activity and local immune modulation.
LDRT Clinical Studies: The Evidence Behind the Standard
The following represents a selection of published research most relevant to the conditions JointGlow treats. Full citations are available upon request.
Dove et al. 2026.
This American Radium Society consensus guideline establishes appropriate use criteria for low-dose radiotherapy in osteoarthritis. The panel confirms LDRT yields 60% to 90% response rates, offering joint-specific recommendations for pain reduction and improved mobility in refractory patients.
Khakshour et al. 2026.
This review highlights the mechanistic rationale for low-dose radiotherapy as an adjunctive osteoarthritis treatment. LDRT modulates the local joint microenvironment by suppressing pro-inflammatory cytokines, boosting anti-inflammatory mediators, and restoring mitochondrial activity without inducing systemic immunosuppression.
Deloch et al. 2025.
This comprehensive review outlines the biological and physical mechanisms of low-dose radiotherapy, highlighting its anti-inflammatory and pain-relieving benefits for treating benign conditions such as osteoarthritis and tendinitis.
Koneru et al. International Journal of Radiation Oncology, Biology, Physics, 2025.
Low-dose radiotherapy achieved significant pain reduction in 80% of treated joints at treatment end, with 72% maintaining relief at 10-week follow-up across multiple joint sites.
Koneru et al. 2025.
This comprehensive chapter explores the pathophysiology and clinical management of periarticular soft tissue disorders, highlighting low-dose radiotherapy as an effective intervention for refractory conditions like plantar fasciitis and lateral epicondylitis.
Koneru, B. N., JointGlow Clinical Review, 2025.
Pooled data analysis across 65 studies demonstrates an overall 75% pain response rate for low-dose radiotherapy in managing osteoarthritis across hand, foot/ankle, knee, and hip joints.
Kim et al. 2024.
In this analysis, comparing kilovoltage and megavoltage energies in low-dose radiotherapy (LDRT) for painful degenerative musculoskeletal conditions, both modalities were found to be similarly effective. The study underscores the versatility of LDRT delivery methods without compromising clinical outcomes.
Koneru & Shaffer 2024.
The establishment of a low-dose radiotherapy program for osteoarthritis at the Leonard Ferguson Cancer Center yielded significant symptomatic relief, with average pain scores dropping from 7/10 to 3/10. LDRT provided enhanced functionality and an alternative for patients lacking surgical options, effectively bridging the gap between conservative medical management and surgical intervention.
Makarova et al. 2023.
Orthovoltage X-ray therapy in 10 fractions significantly reduced disability risk in knee OA patients, showing sustained pain relief and improved function over a decade-long follow-up.
Álvarez et al. Clinical and Translational Oncology, 2022.
Prospective study showing low-dose radiotherapy achieved pain relief in 94% of hand OA patients, significantly reducing pain scores through 12-month follow-up with no acute or late complications.
Dove et al. International Journal of Radiation Oncology, Biology, Physics, 2022.
Critical review of modern literature demonstrating 60% to 90% pain response and functional improvement in osteoarthritis patients treated with low-dose radiotherapy, supporting its safety and cost-effectiveness.
Dove et al. International Journal of Radiation Oncology, Biology, Physics, 2022.
Review of 18 modern studies evaluating low-dose radiotherapy demonstrated significant pain reduction and improved function, with prospective trials reporting up to a 75% response rate.
Exceptionally Well-Studied, Exceptionally Safe
The safety profile of LDRT has been evaluated across the same body of research that established its clinical efficacy. The findings are consistent.
- Total dose across all 6-10 sessions is less than a single standard CT scan
- No increased risk of secondary malignancy at therapeutic doses — confirmed across pooled analyses
- No systemic side effects observed in clinical literature
- The most commonly reported experience is mild, temporary warmth at the treatment site in a subset of patients — resolves within 24 to 48 hours
- All JointGlow treatments are physician-supervised and protocol-standardized
